Hyperfine (HYPR) closed out FY 2025 with Q4 revenue of US$5.3 million and a net loss of US$5.9 million, equal to a basic EPS loss of US$0.06. On a trailing twelve month basis it generated US$13.6 million of revenue and a total net loss of US$35.6 million, or a basic EPS loss of US$0.43. Over the past four reported quarters, revenue has moved from US$2.1 million in Q1 2025 to US$5.3 million in Q4 2025, while quarterly basic EPS losses ranged between US$0.06 and US$0.14 per share. This keeps the focus squarely on how efficiently each new dollar of sales is being converted against still sizable losses. With revenue growth expectations and narrowing losses over recent years in the background, this latest print leaves investors weighing whether margins can tighten enough to eventually support the current story.

See our full analysis for Hyperfine.

With the headline numbers in place, the next step is to set these results against the most common narratives around Hyperfine to see which views the data supports and which ones start to look stretched.

Revenue Momentum With Narrowing Losses

• On a trailing 12 month basis, revenue sits at US$13.6 million while the net loss is US$35.6 million, so sales are growing from a relatively small base while losses remain large in absolute terms.
• Bulls point to strong revenue forecasts of about 39.3% per year and losses reducing at roughly 4.1% per year as a sign that top line growth and improving margins can eventually support a more scalable business model.
  • That view leans heavily on the idea that growing revenue, from US$10.6 million to US$13.6 million on a trailing basis, will keep making the current US$35.6 million loss more manageable over time.
  • It also assumes that recent quarters, where quarterly net losses moved from around US$11.0 million in Q3 2025 to US$5.9 million in Q4 2025, are early evidence of the operating leverage bulls expect to continue.

On these numbers, supporters argue the business is moving in the right direction even though profitability is still some way off, and that is the core of the bullish narrative they are watching unfold. 🐂 Hyperfine Bull Case

High P/S Multiple Keeps Pressure On Execution

• Hyperfine trades on a P/S of 11.7x, compared with roughly 2x for peers and about 2.8x for the wider US Medical Equipment industry, so the current valuation embeds much stronger revenue expectations than those groups.
• Bears focus on this gap, arguing that paying nearly 6x the peer P/S level while the company is still loss making on US$35.6 million of trailing 12 month net losses leaves little room if revenue or margins fall short of forecasts.
  • They also point out that analysts do not expect profitability within the next three years, which means investors are relying on revenue of about US$13.6 million today eventually scaling into much higher future earnings to justify the current multiple.
  • With the current share price around US$1.21 and analysts modelling a price target of US$2.05, the cautious view is that any disappointment against those growth assumptions could matter quickly when starting from a premium P/S.

Skeptics see the rich P/S multiple and ongoing losses as a combination that demands consistently strong execution to support the current share price. 🐻 Hyperfine Bear Case

Quarterly Losses Shrink But Profit Still Distant

• Quarterly net loss improved from US$11.0 million in Q3 2025 to US$5.9 million in Q4 2025, and basic EPS loss narrowed from US$0.14 to US$0.06 over the same period, while the trailing 12 month EPS loss stands at US$0.43.
• Consensus narrative leans on these improving EPS and net loss figures as signs the cost base is becoming more efficient, yet the fact that the business remains unprofitable on US$13.6 million of trailing revenue means the path to positive earnings is still a key question for investors.
  • Trailing 12 month net losses have eased from about US$41.0 million to US$35.6 million across the last six data points, which fits the view that losses have been reducing at roughly 4.1% per year.
  • At the same time, guidance and analysis still point to unprofitability over the next three years, so readers need to judge whether the current pace of loss reduction is enough given the present revenue base and valuation.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Hyperfine on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

These mixed signals on growth, losses and valuation can feel finely balanced, so it makes sense to review the full picture and decide quickly where you stand. To get a rounded view of both the upside and the concerns, take a closer look at the 2 key rewards and 2 important warning signs.

See What Else Is Out There

Hyperfine still reports sizeable net losses on a small revenue base and trades on a rich P/S multiple, so execution risk around profitability and valuation stays high.

If you want ideas where the balance of risk and reward may look more comfortable today, check out 72 resilient stocks with low risk scores to compare companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.